Romain Lazor

Romain Lazor

Auto-generated profile, based on publicly available information

Romain Lazor

Respiratory Medicine Department, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 December 2009 in European Respiratory Journal
Verified
Journal Article
Open access
PDF file
SJS. R. Johnson
S. R. Johnson
JCJ. F. Cordier
J. F. Cordier
RLR. Lazor
R. Lazor
VCV. Cottin
V. Cottin
UCU. Costabel
U. Costabel
TFThe Review Panel Of The Ers Lam Task Force
The Review Panel Of The Ers Lam Task Force
Patients with LAM usually develop progressive dyspnoea and recurrent pneumothorax, chylous collections and occasional haemoptysis 1. Extra pulmonary lymphadenopathy and cystic masses of the axial lymphatics termed lymphangioleiomyomas can result in abdominal and pelvic lymphatic obstruction 7. LAM is often associated with angiomyolipoma in the kidneys 8, and an increased frequency of meningioma 9. LAM varies in clinical features and rate of progression: this together with an absence of clear prognostic factors results in patients being given conflicting information about prognosis.

1 September 2015 in European Journal of Internal Medicine
Verified
Journal Article
Open access
MGMatthieu Groh
Matthieu Groh
CPChristian Pagnoux
Christian Pagnoux
CBChiara Baldini
Chiara Baldini
EBElisabeth Bel
Elisabeth Bel
PBPaolo Bottero
Paolo Bottero
LGLoïc Guillevin
Loïc Guillevin
To develop disease-specific recommendations for the diagnosis and management of eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) (EGPA). The EGPA Consensus Task Force experts comprised 8 pulmonologists, 6 internists, 4 rheumatologists, 3 nephrologists, 1 pathologist and 1 allergist from 5 European countries and the USA. Using a modified Delphi process, a list of 40 questions was elaborated by 2 members and sent to all participants prior to the meeting. Concurrently, an extensive literature search was undertaken with publications assigned with a level of evidence according to accepted criteria. Drafts of the recommendations were circulated for review to all members until final consensus was reached. Twenty-two recommendations concerning the diagnosis, initial evaluation, treatment and monitoring of EGPA patients were established. The relevant published information on EGPA, antineutrophil-cytoplasm antibody-associated vasculitides, hypereosinophilic syndromes and eosinophilic asthma supporting these recommendations was also reviewed. These recommendations aim to give physicians tools for effective and individual management of EGPA patients, and to provide guidance for further targeted research.

1 September 1999 in Medicine
Verified
Journal Article
Closed access
TUThierry Urban
Thierry Urban
RLRomain Lazor
Romain Lazor
JLJacques Lacronique
Jacques Lacronique
MMMarléne Murris
Marléne Murris
SLSylvie Labrune
Sylvie Labrune
DVDominique Valeyre
Dominique Valeyre
Pulmonary lymphangioleiomyomatosis (LAM) is a rare disorder of unknown cause characterized by peribronchial, perivascular, and perilymphatic proliferation of abnormal smooth muscle cells leading to cystic lesions. The hypothesis of hormonal dependence and the effectiveness of hormonal therapy have not yet been demonstrated conclusively, and the prevalence of extrathoracic manifestations and the survival of patients with LAM are somewhat contradictory. A multicentric retrospective study was conducted in an attempt to describe better the initial features, the diagnostic procedures, the associated lesions, and, above all, the management and course of LAM in a large homogeneous series of 69 stringently selected patients, with a majority of cases diagnosed since 1990. The aim of the study, based on a review of the literature, also was to provide a comprehensive view of this uncommon disease. The clinical features were in keeping with previous studies, but we found that exertional dyspnea and pneumothorax were the most common features, and chylous involvement was less frequent. LAM was diagnosed after menopause in about 10% of cases. The onset of LAM occurred during pregnancy in 20% of cases, and a clear exacerbation of LAM was observed in 14% of cases during pregnancy. Pulmonary LAM was diagnosed on lung histopathology in 83% of cases, but renal angiomyolipoma, observed in 32% of our patients, may be a useful diagnostic criterion when associated with typical multiple cysts on chest CT scan or with chylous effusion. Chest CT scan was more informative than chest X-ray (normal in 9% of cases), and may be indicated in spontaneous pneumothorax or renal angiomyolipoma in women of childbearing age. About 40% of the patients had a normal initial spirometry, while an obstructive ventilatory defect (44%), a restrictive ventilatory defect (23%), was observed in other patients. Initial diffusing capacity for carbon monoxide was frequently decreased (82%). Hormonal therapy was administered in 57 patients, but a clear > or = 15% improvement of FEV1 was observed in only 4 evaluable patients, treated with tamoxifen and progestogens (n = 2), progestogen (n = 1), and oophorectomy (n = 1). Probably 1 of the most urgent needs for clinical research in LAM is to test the currently available hormonal treatments in the context of international multicenter prospective controlled studies. Pleurodesis was performed in 40 patients. Lung transplantation was performed in 13 patients, 7.8 +/- 5.2 years after onset of LAM, in whom the mean FEV1 was 0.57 +/- 0.15 L. After a follow-up of 2.3 +/- 2.2 years, 9 patients were alive. Mean follow-up from onset of disease to either death or closing date was 8.2 +/- 6.3 years. Overall survival was better than usually reported in LAM, and Kaplan-Meier plot showed survival probabilities of 91% after 5 years, 79% after 10 years, and 71% after 15 years of disease duration.

1 July 2000 in Medicine
Verified
Journal Article
Closed access
DLDominique Lauque
Dominique Lauque
JCJacques Cadranel
Jacques Cadranel
RLRomain Lazor
Romain Lazor
JPJacques Pourrat
Jacques Pourrat
PRPierre Ronco
Pierre Ronco
JCJean-François Cordier
Jean-François Cordier
Microscopic polyangiitis (MPA) is a systemic small-vessel vasculitis primarily associated with necrotizing glomerulonephritis and pulmonary capillaritis. In this retrospective study of 29 patients with MPA and alveolar hemorrhage (AH), we characterized the pulmonary manifestations at presentation and assessed the short- and long-term outcome. AH was diagnosed when bronchoalveolar lavage was macroscopically bloody, or contained hemosiderin-laden macrophages, in the absence of lung infection or pulmonary edema. MPA was diagnosed when AH was associated with focal segmental necrotizing glomerulonephritis at kidney biopsy or pathologically proved small-vessel vasculitis. There were 17 women and 12 men, with a mean age of 55.8 +/- 16.7 years. The onset was rapidly progressive, but in 8 (28%) patients, symptoms preceded the diagnosis for more than 1 year. The most constant systemic findings associated with AH were glomerulonephritis in 28 (97%) patients; fever (62%); myalgia and arthralgia (52%); weight loss (45%); ear, nose, and throat symptoms (31%); and skin involvement (17%). Lung opacities were bilateral in 26 (90%) patients, most frequently involving the lower part of the lungs. Bronchoalveolar lavage, performed in 27 patients, was hemorrhagic in 25 (93%), and contained numerous siderophages in others. Most patients were severely anemic (mean hemoglobin, 8.1 +/- 1.8 g/dL). ANCA, present in 27 (93%) patients, gave a perinuclear (14), cytoplasmic (11), or mixed (1) pattern. Mean serum creatinine level was 407 +/- 415 mumol/L. Renal biopsy confirmed the presence of necrotizing glomerulonephritis in 27 patients. Patients were treated with corticosteroids (100%), cyclophosphamide (79%), plasmapheresis (24%), dialysis (28%), and mechanical ventilation (10%). The overall mortality rate was 31% (9 patients). Deaths were related to vasculitis (5 patients) or side effects of treatment (4). Deaths were more frequent in aged or mechanically ventilated patients. The 5-year survival rate was 68%. The recovery of respiratory function among survivors was clinically considered complete in 20 (69%) patients. However, 7 patients (24%) had persistent alterations on pulmonary function tests. Of the 11 patients who had relapses, 2 died from AH.

8 October 2010 in Arthritis & Rheumatism
Verified
Journal Article
Open access
PDF file
VCVincent Cottin
Vincent Cottin
HNHilario Nunes
Hilario Nunes
LMLuc Mouthon
Luc Mouthon
DGDelphine Gamondes
Delphine Gamondes
RLRomain Lazor
Romain Lazor
GPGroupe D'ETudes Et de Recherche Sur Les Maladies “Orphelines” Pulmonaires
Groupe D'ETudes Et de Recherche Sur Les Maladies “Orphelines” Pulmonaires
Objective: Connective tissue diseases (CTDs) are associated with several interstitial lung diseases. The aim of this study was to describe the recently individualized syndrome of combined pulmonary fibrosis and emphysema (CPFE) in a population of patients with CTD.Methods: In this multicenter study, we retrospectively investigated data from patients with CTD who also have CPFE. The demographic characteristics of the patients, the results of pulmonary function testing, high‐resolution computed tomography, lung biopsy, and treatment, and the outcomes of the patients were analyzed.Results: Data from 34 patients with CTD who were followed up for a mean ± SD duration of 8.3 ± 7.0 years were analyzed. Eighteen of the patients had rheumatoid arthritis (RA), 10 had systemic sclerosis (SSc), 4 had mixed or overlap CTD, and 2 had other CTDs. The mean ± SD age of the patients was 57 ± 11 years, 23 were men, and 30 were current or former smokers. High‐resolution computed tomography revealed emphysema of the upper lung zones and pulmonary fibrosis of the lower zones in all patients, and all patients exhibited dyspnea during exercise. Moderately impaired pulmonary function test results and markedly reduced carbon monoxide transfer capacity were observed. Five patients with SSc exhibited pulmonary hypertension. Four patients died during followup. Patients with CTD and CPFE were significantly younger than an historical control group of patients with idiopathic CPFE and more frequently were female. In addition, patients with CTD and CPFE had higher lung volumes, lower diffusion capacity, higher pulmonary pressures, and more frequently were male than those with CTD and lung fibrosis without emphysema.Conclusion: CPFE warrants inclusion as a novel, distinct pulmonary manifestation within the spectrum of CTD‐associated lung diseases in smokers or former smokers, especially in patients with RA or SSc.

10 June 2012 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
GBGrégoire Berthod
Grégoire Berthod
RLRomain Lazor
Romain Lazor
ILIgor Letovanec
Igor Letovanec
EREmanuela Romano
Emanuela Romano
LNLeslie Noirez
Leslie Noirez
OMOlivier Michielin
Olivier Michielin